News | March 18, 2021
Merck accelerates expansion plans for single-use products critical to manufacturing vaccines
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This approval authorizes the company to export Ibuprofen to the Chinese markets
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Delivers robust earnings performance, successfully navigating a dynamic environment
Subscribe To Our Newsletter & Stay Updated
